Belenos Biosciences

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
TSLP + IL-13Multispecific antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaChronic Spontaneous Urticaria

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
July 2027 (1)
CM512Phase 2Asthma
Est. primary completion 2027-07-21 · NCT07011524 · CT.gov ↗
What to watch
November 2027 (1)
CM512Phase 3Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Est. primary completion 2027-11 · NCT07807826 · CT.gov ↗
What to watch
December 2027 (1)
CM512Phase 2Atopic Dermatitis (AD)
Est. primary completion 2027-12 · NCT07230483 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
CM512Phase 2Chronic Obstructive Pulmonary Disease
Est. primary completion 2028-03-17 · NCT06980142 · CT.gov ↗
What to watch
May 2028 (1)
CM512Phase 2Chronic Rhinosinusitis With Nasal Polyposis
Est. primary completion 2028-05-31 · NCT07519577 · CT.gov ↗
What to watch
June 2028 (1)
CM512Phase 2Perennial Allergic Rhinitis (PAR)
Est. primary completion 2028-06 · NCT07890350 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

August 2026Topline resultCM512Phase 2 of CM512 in chronic rhinosinusitis with nasal polyps (China, NCT06930612) met its primary endpoint

Financial reports

No financial reports recorded.